Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
siSRF797 is a small interfering RNA (siRNA) drug candidate targeting serum response factor (SRF) mRNA. Its mechanism involves the selective silencing of the SRF gene by promoting the degradation of its messenger RNA, thereby reducing SRF protein levels. SRF is a transcription factor implicated in fibrosis and various pathologies; thus, siSRF797 is primarily being researched for disorders related to fibrosis and pathological tissue remodeling. The specific developer and manufacturing companies have not been identified in publicly available sources. siSRF797 is under preclinical or early clinical investigation; no marketing approval has been reported.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on siSRF797.